Genomics

An AI firm known for fighting cancer is now partnering with Unilever, signaling a new era of biologically personalized consumer products and new ethical questions.

Zoetis is acquiring Neogen's genomics unit for $160M, a strategic move set to accelerate data-driven innovation in livestock and companion animal care.

With $28M in funding and a star-studded advisory board, a new biotech firm aims to turn routine dental visits into a frontline defense against oral cancer.

Nautilus Biotechnology cuts losses and preps its Voyager platform for a late 2026 launch, targeting the next frontier in neurodegenerative disease research.

Nabsys's electronic genome mapping reveals how rogue genetic elements damage our DNA, opening new frontiers in understanding cancer and neurodegeneration.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

New England Biolabs is launching next-gen sample prep tools, targeting long-read sequencing, RNA bias, and clinical epigenetics to accelerate discovery.

Element Biosciences unveils VITARI, a high-throughput benchtop sequencer promising a $100 whole genome, challenging market giants and democratizing genomics.

Watchmaker Genomics is repurposing CRISPR, not for editing genes, but to make DNA sequencing faster, cheaper, and more reliable than ever before.

A genomic test identifies which breast cancer patients truly benefit from extended hormone therapy, a major step toward personalized long-term care.

A new genomics tracker reveals the fragmented adoption of precision cancer care across the EU-5, highlighting critical barriers and strategic opportunities.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

Blue Cross and MassChallenge award five startups $50k each to solve critical health disparities, from endometriosis diagnosis to language access in hospitals.

A new integrated test from NeoGenomics aims to slash diagnostic delays and streamline complex tumor profiling, promising faster, smarter cancer treatment.

As Caroline Dorsa retires, Biogen elects Dr. Maria Freire as its new chair, a strategic move placing deep scientific expertise at the helm for a critical period.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

After a decade-long battle with Stage 4 cancer, one patient's cure spotlights a revolutionary immunotherapy and its potential to change cancer treatment.

With its Phase 1 trial fully enrolled, Senti Bio’s logic-gated CAR-NK therapy shows deep, durable remissions, charting an expedited path for R/R AML.

Katherine Stueland’s honor underscores a major shift in healthcare, as genomic screening and AI promise to end the diagnostic odyssey for rare diseases.